目的观察慢性肺源性心脏病合并右心衰竭患者的血内皮素(ET-1)、一氧化氮(NO)、肺动脉收缩压(PASP)水平,探讨法舒地尔对各项指标的影响及临床意义。方法将60例患者随机分为常规治疗组和实验组(法舒地尔组)各30例,实验组在内科常规治疗基础上加用法舒地尔60mg+0.9%氯化钠注射液100mL静脉滴注,1次/d,2周1疗程。同时分别测定两组患者治疗前后的ET-1和NO水平,心脏超声测定PASP水平。另选取30例健康体检者做为健康对照组,检测上述指标。结果治疗后两组患者临床症状均有缓解,实验组症状缓解更明显,且实验组的NO水平升高更明显,ET-1、PASP水平降低更明显。结论法舒地尔后能明显改善慢性肺心病合并右心衰的临床症状,降低肺动脉收缩压,可能机制与降低ET-1,升高NO,降低PAH有关,其长期疗效还有待进一步研究。 Objective To observe the levels of endothelin (ET), nitric oxide (NO) and pulmonary artery systolic pressure (PASP) in patients with chronic cor pulmonale complicated with right heart failure (CHF) Clinical significance. Methods Sixty patients were randomly divided into routine treatment group and experimental group (fasudil group), 30 cases in each group. The experimental group received 100 mL intravenous infusion of fasudil 60 mg + 0.9% sodium chloride injection on the basis of routine medical treatment Note, 1 / d, 2 weeks 1 course of treatment. At the same time, the levels of ET-1 and NO before and after treatment were measured in both groups, and the level of PASP was measured by echocardiography. Another 30 healthy subjects were selected as healthy control group, the above indicators were measured. Results After treatment, the clinical symptoms of both groups were relieved. The symptom relief in the experimental group was more obvious. The NO level in the experimental group increased more obviously, and the levels of ET-1 and PASP decreased more obviously. Conclusions Fasudil can obviously improve the clinical symptoms and reduce the pulmonary systolic pressure in patients with chronic cor pulmonale complicated with right heart failure. The possible mechanism is related to decreasing ET-1, increasing NO and decreasing PAH. The long-term therapeutic effect remains to be further studied.